MX2020013166A - Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca. - Google Patents
Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca.Info
- Publication number
- MX2020013166A MX2020013166A MX2020013166A MX2020013166A MX2020013166A MX 2020013166 A MX2020013166 A MX 2020013166A MX 2020013166 A MX2020013166 A MX 2020013166A MX 2020013166 A MX2020013166 A MX 2020013166A MX 2020013166 A MX2020013166 A MX 2020013166A
- Authority
- MX
- Mexico
- Prior art keywords
- anca
- human
- antagonist
- dosage
- effect
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682013P | 2018-06-07 | 2018-06-07 | |
| PCT/US2019/035758 WO2019236820A1 (en) | 2018-06-07 | 2019-06-06 | Dosing and effect of c5a antagonist with anca-associated vasculitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013166A true MX2020013166A (es) | 2021-03-29 |
Family
ID=68764799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013166A MX2020013166A (es) | 2018-06-07 | 2019-06-06 | Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11191756B2 (OSRAM) |
| EP (1) | EP3801519A4 (OSRAM) |
| JP (2) | JP2021527062A (OSRAM) |
| KR (2) | KR20210018906A (OSRAM) |
| CN (1) | CN112423752A (OSRAM) |
| AU (1) | AU2019282327B2 (OSRAM) |
| BR (1) | BR112020024842A2 (OSRAM) |
| CA (1) | CA3102403A1 (OSRAM) |
| CL (1) | CL2020003171A1 (OSRAM) |
| IL (1) | IL279188B2 (OSRAM) |
| MA (1) | MA52808A (OSRAM) |
| MX (1) | MX2020013166A (OSRAM) |
| SG (1) | SG11202011961YA (OSRAM) |
| WO (1) | WO2019236820A1 (OSRAM) |
| ZA (1) | ZA202007615B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3102403A1 (en) | 2018-06-07 | 2019-12-12 | Chemocentryx, Inc. | Dosing and effect of c5a antagonist with anca-associated vasculitis |
| EP4487915A3 (en) | 2018-11-30 | 2025-03-19 | ChemoCentryx, Inc. | Capsule formulations |
| MX2022005406A (es) | 2019-11-08 | 2022-05-24 | Chemocentryx Inc | Forma amorfa de un receptor de componente c5a de complemento. |
| CN118908883A (zh) * | 2019-11-08 | 2024-11-08 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| WO2008079371A1 (en) * | 2006-12-22 | 2008-07-03 | Encysive Pharmaceuticals, Inc. | Modulators of c3a receptor and methods of use thereof |
| CN104193824A (zh) * | 2008-02-20 | 2014-12-10 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
| US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| SMT202200074T1 (it) | 2008-12-22 | 2022-03-21 | Chemocentryx Inc | Antagonisti di c5ar |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| EP3682879B1 (en) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| EP3283889B1 (en) | 2015-04-17 | 2020-02-26 | Euroimmun Medizinische Labordiagnostika AG | Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject |
| WO2017176620A2 (en) | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | SOLUBLE C5aR ANTAGONISTS |
| US20190134020A1 (en) * | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | C5aR INHIBITOR REDUCTION OF URINARY sCD163 |
| CA3102403A1 (en) | 2018-06-07 | 2019-12-12 | Chemocentryx, Inc. | Dosing and effect of c5a antagonist with anca-associated vasculitis |
-
2019
- 2019-06-06 CA CA3102403A patent/CA3102403A1/en active Pending
- 2019-06-06 SG SG11202011961YA patent/SG11202011961YA/en unknown
- 2019-06-06 KR KR1020217000253A patent/KR20210018906A/ko not_active Ceased
- 2019-06-06 BR BR112020024842-8A patent/BR112020024842A2/pt unknown
- 2019-06-06 AU AU2019282327A patent/AU2019282327B2/en active Active
- 2019-06-06 EP EP19814841.3A patent/EP3801519A4/en active Pending
- 2019-06-06 CN CN201980038855.4A patent/CN112423752A/zh active Pending
- 2019-06-06 JP JP2020567973A patent/JP2021527062A/ja active Pending
- 2019-06-06 MA MA052808A patent/MA52808A/fr unknown
- 2019-06-06 KR KR1020267004102A patent/KR20260027358A/ko active Pending
- 2019-06-06 MX MX2020013166A patent/MX2020013166A/es unknown
- 2019-06-06 US US16/433,487 patent/US11191756B2/en active Active
- 2019-06-06 WO PCT/US2019/035758 patent/WO2019236820A1/en not_active Ceased
- 2019-06-06 IL IL279188A patent/IL279188B2/en unknown
-
2020
- 2020-12-04 CL CL2020003171A patent/CL2020003171A1/es unknown
- 2020-12-07 ZA ZA2020/07615A patent/ZA202007615B/en unknown
-
2021
- 2021-11-04 US US17/519,266 patent/US12350263B2/en active Active
-
2024
- 2024-05-30 JP JP2024088364A patent/JP2024114706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021527062A (ja) | 2021-10-11 |
| CN112423752A (zh) | 2021-02-26 |
| JP2024114706A (ja) | 2024-08-23 |
| EP3801519A1 (en) | 2021-04-14 |
| BR112020024842A2 (pt) | 2021-03-02 |
| SG11202011961YA (en) | 2020-12-30 |
| US12350263B2 (en) | 2025-07-08 |
| US11191756B2 (en) | 2021-12-07 |
| KR20210018906A (ko) | 2021-02-18 |
| WO2019236820A1 (en) | 2019-12-12 |
| US20190374524A1 (en) | 2019-12-12 |
| EP3801519A4 (en) | 2022-03-30 |
| AU2019282327B2 (en) | 2025-04-24 |
| CL2020003171A1 (es) | 2021-06-04 |
| AU2019282327A1 (en) | 2021-01-07 |
| MA52808A (fr) | 2021-04-14 |
| IL279188B1 (en) | 2025-12-01 |
| IL279188B2 (en) | 2026-04-01 |
| KR20260027358A (ko) | 2026-02-27 |
| ZA202007615B (en) | 2024-05-30 |
| IL279188A (en) | 2021-01-31 |
| US20220296576A1 (en) | 2022-09-22 |
| CA3102403A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002321A (es) | Nuevos metodos. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2021002322A (es) | Nuevos metodos. | |
| CL2020003171A1 (es) | Dosis y efecto de un antagonista de c5a con una vasculitis asociada a anca. | |
| MX2020011653A (es) | Métodos de tratamiento para el abuso de sustancias. | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2020003421A (es) | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). | |
| MX2022000143A (es) | Metodos novedosos. | |
| EA201791576A1 (ru) | Ингибитор jak | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
| EA202091640A1 (ru) | Способы лечения опосредованного il-6 воспаления без иммунодепрессии | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| MX2016011115A (es) | Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1. | |
| EA202090164A1 (ru) | Изотретиноиновые перорально-слизистые композиции и способы их применения | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias |